{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:41:58Z","timestamp":1780695718611,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:p>Evidence on real-world clinical and economic outcomes in patients with multiple myeloma (MM) and renal impairment (RI) is limited in the United States. This retrospective study aimed to generate an updated comprehensive assessment of the clinical and economic outcomes of MM patients with RI using the Medicare research identifiable files data with Part D linkage, which might assist in assessing the total clinical and socioeconomic burden of these high-risk and challenging-to-treat patients. Treatment patterns and clinical and economic outcomes in first line (1L) to fourth line (4L) therapy were described in Medicare beneficiaries (2012 to 2018) for MM patients with RI (RI MM cohort). For reference purposes, information on a general cohort of MM patients was generated and reported to highlight the clinical and economic burden of RI. Since the goal was to describe the burden of these patients, this study was not designed as a comparison between the 2 cohorts. Compared with the general MM cohort (n\u2005=\u200513,573), RI MM patients (24.9%) presented high MM-associated comorbidities. In the RI MM cohort, bortezomib\u2013dexamethasone (45.7%), bortezomib\u2013lenalidomide (18.6%), lenalidomide (12.3%), and bortezomib\u2013cyclophosphamide (12.1%) were the most prevalent regimens in 1L; carfilzomib and pomalidomide were mostly received in 3L to 4L; and daratumumab in 4L. Across 1L to 4L, the RI MM cohort presented shorter median real-world progression-free survival (1L: 12.9 and 16.4 months) and overall survival (1L: 31.1 and 46.8 months) and higher all-cause healthcare resource utilization (1L incidence rate of inpatient days: 12.1 and 7.8 per person per year) than the general MM cohort. In the RI MM cohort, the mean all-cause total cost increased from 1L to 4L ($14,549\u2013$18,667 per person per month) and was higher than that of the general MM cohort. RI MM patients presented higher clinical and economic burdens across 1L to 4L than the general MM patients in real-world clinical practice.<\/jats:p>","DOI":"10.1097\/md.0000000000038609","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:47:13Z","timestamp":1719586033000},"page":"e38609","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-297X","authenticated-orcid":false,"given":"Parameswaran","family":"Hari","sequence":"first","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Lin","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Sasane","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260223","doi-asserted-by":"crossref","first-page":"A141","DOI":"10.1016\/j.jval.2016.03.2006","article-title":"Prevalence of renal impairment in patients with multiple myeloma: analysis of real-world database.","volume":"19","author":"Bhowmik","year":"2016","journal-title":"Value Health"},{"key":"R2-20260223","doi-asserted-by":"crossref","first-page":"e23416","DOI":"10.1002\/jcla.23416","article-title":"Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.","volume":"34","author":"Chen","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"R3-20260223","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma.","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"R4-20260223","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cam4.1075","article-title":"Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.","volume":"6","author":"Qian","year":"2017","journal-title":"Cancer Med"},{"key":"R5-20260223","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1078155218766408","article-title":"Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.","volume":"25","author":"Bhowmik","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"15_suppl","key":"R6-20260223","doi-asserted-by":"crossref","first-page":"e18922","DOI":"10.1200\/JCO.2018.36.15_suppl.e18922","article-title":"Healthcare resource utilization (HRU) and costs associated with renal impairment (RI) among treated multiple myeloma (MM) patients.","volume":"36","author":"Medhekar","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20260223","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.","volume":"107","author":"Capra","year":"2022","journal-title":"Haematologica"},{"key":"R8-20260223","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ckj\/sfy065","article-title":"Treatment of multiple myeloma with renal involvement: the nephrologist\u2019s view.","volume":"11","author":"Fava","year":"2018","journal-title":"Clin Kidney J"},{"key":"R9-20260223","doi-asserted-by":"crossref","first-page":"20406207221088458","DOI":"10.1177\/20406207221088458","article-title":"An overview of treatment options for patients with relapsed\/refractory multiple myeloma and renal impairment.","volume":"13","author":"Dimopoulos","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"R10-20260223","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment.","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-20260223","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000328417","article-title":"A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?","volume":"126","author":"Piro","year":"2011","journal-title":"Acta Haematol"},{"key":"R12-20260223","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14656566.8.4.497","article-title":"The evolving role of lenalidomide in the treatment of hematologic malignancies.","volume":"8","author":"Kastritis","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R13-20260223","doi-asserted-by":"crossref","first-page":"26348535211042012","DOI":"10.1177\/26348535211042012","article-title":"Experience of daratumumab in six patients with multiple myeloma and kidney failure.","volume":"15","author":"Turgutkaya","year":"2021","journal-title":"Plasmatology"},{"issue":"Suppl","key":"R14-20260223","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.","volume":"15 Suppl","author":"Faiman","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"R15-20260223","first-page":"e22585","article-title":"Multiple myeloma and renal failure: mechanisms, diagnosis, and management.","volume":"14","author":"Kundu","year":"2022","journal-title":"Cureus"},{"key":"R16-20260223","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"R17-20260223","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae insights: multiple myeloma, version 3.2022.","volume":"20","author":"Kumar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R18-20260223","first-page":"236","article-title":"Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib.","volume":"23","author":"Chen","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R19-20260223","year":"2021"},{"key":"R20-20260223","doi-asserted-by":"crossref","first-page":"e101819","DOI":"10.1371\/journal.pone.0101819","article-title":"The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.","volume":"9","author":"Uttervall","year":"2014","journal-title":"PLoS One"},{"key":"R21-20260223","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/j.clml.2019.05.010","article-title":"Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand myeloma and related diseases registry.","volume":"19","author":"Ho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R22-20260223","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2014.118182","article-title":"Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.","volume":"100","author":"Moreau","year":"2015","journal-title":"Haematologica"},{"key":"R23-20260223","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"key":"R24-20260223","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00432-013-1513-2","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.","volume":"139","author":"Ponisch","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"R25-20260223","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"R26-20260223","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood.V124.21.4755.4755","article-title":"Pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma and renal impairment: analysis of patients from the phase 3b stratus trial (MM-010).","volume":"124","author":"Weisel","year":"2014","journal-title":"Blood"},{"key":"R27-20260223","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a phase II trial.","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R28-20260223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.","volume":"11","author":"Baertsch","year":"2021","journal-title":"Blood Cancer J"},{"key":"R29-20260223","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis.","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20260223","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2019-0422","article-title":"Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.","volume":"15","author":"Hari","year":"2019","journal-title":"Future Oncol"},{"key":"R31-20260223","first-page":"690","article-title":"Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?","volume":"18","author":"Tungol","year":"2012","journal-title":"J Manag Care Pharm"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:00:58Z","timestamp":1771884058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":31,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038609","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}